Phase I Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2019
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 24 Dec 2018 Status changed from not yet recruiting to recruiting.
- 16 Oct 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
- 08 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Oct 2018.